HB 5175 would amend Connecticut’s general statutes to require every pharmacy licensed in the state to take two actions when dispensing prescription drugs. First, pharmacies would have to apply all available discounts or coupons to a prescription drug purchase. Second, before presenting a prescription to a customer, pharmacies would have to notify the customer about any available prescription drug discount programs and generic alternatives that could reduce the price.
The bill is aimed at lowering out-of-pocket prescription costs for consumers by making price-reduction options more visible and more consistently used at the point of sale. It would place a new affirmative duty on licensed pharmacies to identify and communicate savings opportunities, potentially affecting pharmacy billing practices, customer interactions, and the use of brand-name versus generic medications.
Impact
If enacted, the bill would add new consumer-protection and disclosure requirements to Connecticut pharmacy law. Licensed pharmacies would need to ensure that available coupons, discount programs, and generic substitution options are considered and communicated before a prescription is finalized, which could affect pharmacy workflow, software systems, and compliance procedures. The practical effect would be to push pharmacies toward maximizing lower-cost options for patients and to increase transparency around prescription pricing.
Sentiment
Based on the bill text and the absence of recorded committee testimony or votes in the provided materials, the overall sentiment appears supportive of reducing prescription drug costs for consumers. The proposal is framed as a cost-savings and transparency measure rather than a regulatory restriction, suggesting a consumer-oriented policy goal. No formal opposition, amendments, or recorded vote outcomes are available in the provided context.
Contention
The main potential points of contention are likely to involve implementation and responsibility. Pharmacies may object to being required to apply all available discounts or coupons, especially where coupon eligibility, insurer rules, or manufacturer program terms are complex or may conflict with existing billing processes. Another possible issue is the mandate to notify customers about generic alternatives and discount programs, which could raise questions about timing, accuracy, administrative burden, and whether pharmacies are being asked to provide advice that overlaps with prescriber or insurer functions. No specific opposing viewpoints are documented in the provided transcripts or votes.